Axsome Therapeutics, Inc (AXSM) is a publicly traded Healthcare sector company. As of May 21, 2026, AXSM trades at $231.00 with a market cap of $11.70B and a P/E ratio of -61.59. AXSM moved +1.82% today. Year to date, AXSM is +34.48%; over the trailing twelve months it is +112.85%. Its 52-week range spans $75.56 to $235.92. Analyst consensus is strong buy with an average price target of $261.88. Rallies surfaces AXSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Axsome jumps as Q1 sales surge 57% and AUVELITY Alzheimer’s approval boosts outlook: Axsome Therapeutics shares rose after the company posted Q1 2026 net product revenue of $191.2 million, up 57% year over year, led by AUVELITY sales of $153.2 million. Momentum also followed an FDA approval for AUVELITY in Alzheimer’s disease agitation and an NDA submission for AXS-12 in narcolepsy.
| Metric | Value |
|---|---|
| Price | $231.00 |
| Market Cap | $11.70B |
| P/E Ratio | -61.59 |
| EPS | $-3.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $235.92 |
| 52-Week Low | $75.56 |
| Volume | 7 |
| Avg Volume | 0 |
| Revenue (TTM) | $708.24M |
| Net Income | $-188.30M |
| Gross Margin | 0.00% |
19 analysts cover AXSM: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $261.88.